title: Lack of effect of oral administration of resveratrol in LPS-induced systemic inflammation.
abstract: OBJECTIVE
  The high mortality index due to sepsis and the lack of an effective treatment requires the search for new compounds that can serve as therapy for this disease. Resveratrol, a well-known anti-inflammatory natural compound, might be a good candidate for the treatment of sepsis. The aim of this work was to study the effects of oral administration of resveratrol, before and after sepsis initiation, on inflammation markers in a murine model of endotoxin-induced sepsis.
  
  
  METHODS
  Sprague-Dawley male rats were treated with resveratrol the 3 days prior to LPS administration and 45 min later. Hematological parameters, TNF-α, IL-1β and CINC-1, FRAP and TBARS levels were determined. Resveratrol and resveratrol-derived metabolites profile in plasma was compared after oral and intraperitoneal administration.
  
  
  RESULTS
  Oral treatment with resveratrol had no apparent systemic protective effects. However, resveratrol reduced the levels of lipid peroxidation in the small intestine and colon. Importantly, the administration of LPS caused a decrease in resveratrol absorption. When resveratrol bioavailability after i.p. administration was compared to that observed after oral administration, a different profile of resveratrol metabolites was found in plasma.
  
  
  CONCLUSIONS
  These results highlight the importance of studying the bioavailability of the assayed compounds in the experimental models used to be able to choose the best route of administration depending on the target organ and to determine which compounds or derived metabolites are effective treating the studied disease.
authors.affiliation: Department of Food Science and Technology, Research Group on Quality, Safety and Bioactivity of Plant Foods, CEBAS-CSIC, Campus de Espinardo, 30100, Murcia, Spain. marlarrosa@cebas.csic.es
authors.forename: M
authors.initials: M
authors.lastname: Larrosa
authors.forename: M
authors.initials: M
authors.lastname: Azorín-Ortuño
authors.forename: M J
authors.initials: MJ
authors.lastname: Yañez-Gascón
authors.forename: M T
authors.initials: MT
authors.lastname: García-Conesa
authors.forename: F
authors.initials: F
authors.lastname: Tomás-Barberán
authors.forename: J C
authors.initials: JC
authors.lastname: Espín
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000975:Antioxidants / Q000378:metabolism; D002853:Chromatography, Liquid; D004731:Endotoxins / Q000633:toxicity; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy*; D053583:Interleukin-1beta / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008070:Lipopolysaccharides / Q000633:toxicity*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D018805:Sepsis / Q000188:drug therapy*; D013267:Stilbenes / Q000494:pharmacology*; D053719:Tandem Mass Spectrometry; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D004731:Endotoxins; D053583:Interleukin-1beta; D008070:Lipopolysaccharides; D013267:Stilbenes; D017392:Thiobarbituric Acid Reactive Substances; D014409:Tumor Necrosis Factor-alpha; D000077185:Resveratrol